[Problem] The purpose of the present invention is to provide a novel technique associated with anti-obesity improvement.

[Solution] The present invention relates to an anti-obesity agent comprising lactononadecapeptide (LNDP, Asn-Ile-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu) or a salt thereof. The present invention also relates to a pollakiuria improving agent and an autonomic nerve activity regulator each comprising LNDP.

A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.

A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.

An injectable elastin-like recombinamer (ELR) hydrogel for use in a method of treating a mammal that has suffered a myocardial infarction to modulate the response of cardiac muscle damaged by the infarct is described. The hydrogel is injected into the cardiac muscle damaged by the infarct at least two days after the myocardial infarction, and results in clinically significant repair of cardiac muscle evidenced by at least one or more of reduced scarring, positive remodelling of the damaged muscle, restoring cardiac muscle function to a clinically significant extent after infarction an improvement in angiogenesis, or a decreased pro-inflammatory response in the infarct zone, and typically within 10, 20 or 30 days of administration.

The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.

This present invention relates to forms of methyl {4.6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3.4-b]pyridino-3-yl]pyrimidino-5-yl}methylcarbamate comprising its Modification I. Modification II. mono-DMSO solvate. sesqui-DMSO solvate and ¼-ethyl acetate solvate.

This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, a pharmaceutically acceptable salt thereof, or a combination therefore that can be administered to a human subject in need thereof in a supine position. The disclosure also provides pharmaceutical compositions which can be administered once-a-day. This disclosure further provides pharmaceutical compositions comprising an extended release composition and providing a delayed release period between about 30 min to about 12 hours.

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. Their use as radio- and chemo-protectors is also described.

The present invention relates to composition, formulations and devices for preventing vasovagal syncope attack, and in particular to the use of combinations of capsaicin, caffeine, and/or α-agonists to prevent syncope.

The present invention relates to composition, formulations and devices for preventing vasovagal syncope attack, and in particular to the use of combinations of capsaicin, caffeine, and/or α-agonists to prevent syncope.